Baker Bros. Advisors LP Maintains Significant Stake in Replimune

TL;DR

**Baker Bros. Advisors LP still owns a big chunk of Replimune, signaling continued institutional confidence.**

AI Summary

Baker Bros. Advisors LP, a major investment firm, filed an amended SC 13G/A on January 10, 2024, indicating their ownership of Replimune Group, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued significant stake in the biotech company. For investors, this signals that a prominent institutional investor maintains confidence in Replimune, which could be seen as a positive indicator for the stock's long-term prospects.

Why It Matters

This filing shows that a major institutional investor, Baker Bros. Advisors LP, continues to hold a substantial position in Replimune Group, Inc., which can be interpreted as a vote of confidence in the company's future.

Risk Assessment

Risk Level: low — This filing is an update on existing ownership by a major institutional investor, not a new or sudden change, indicating stability.

Analyst Insight

A smart investor would note Baker Bros.' continued stake as a potential positive signal, but would still conduct their own due diligence on Replimune's fundamentals and pipeline before making any investment decisions.

Key Players & Entities

• Baker Bros. Advisors LP (company) — the reporting person and institutional investor
• Replimune Group, Inc. (company) — the subject company whose securities are being reported
• Felix J. Baker (person) — a group member of Baker Bros. Advisors (GP) LLC
• Julian C. Baker (person) — a group member of Baker Bros. Advisors (GP) LLC
• Delaware (company) — place of organization for Baker Bros. Advisors LP
• December 31, 2023 (date) — date of event requiring the filing
• January 10, 2024 (date) — date the filing was made
• 0001737953 (number) — Central Index Key (CIK) for Replimune Group, Inc.
• 0001263508 (number) — Central Index Key (CIK) for Baker Bros. Advisors LP
• 76029N106 (number) — CUSIP Number for Replimune Group, Inc. Common Stock

Forward-Looking Statements

• Baker Bros. Advisors LP will likely maintain a significant stake in Replimune Group, Inc. for the foreseeable future. (Baker Bros. Advisors LP) — medium confidence, target: 2025-01-10
• Replimune Group, Inc. will continue to be a focus for institutional investors interested in biological products. (Replimune Group, Inc.) — medium confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $0.0001 — to Common Stock at an exercise price of $0.0001 per share with no expiration date (the

Filing Documents

• tm242424d1_sc13ga.htm (SC 13G/A) — 86KB
• 0001104659-24-003007.txt ( ) — 88KB

(a)

Item 1(a) Name of Issuer: Replimune Group, Inc. (the “Issuer”)

(b)

Item 1(b) Address of Issuer’s Principal Executive Offices: 500 Unicorn Park Drive, Suite 303 Woburn, MA 01801

(a)

Item 2(a) Name of Person Filing: This Amendment No. 1 is being filed jointly by the Reporting Persons.

(b)

Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690

(c)

Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

(d)

Item 2(d) Title of Class of Securities: Common Stock, $0.001 par value per share (“Common Stock”)

(e)

Item 2(e) CUSIP Number: 76029N106 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) Investment company registered under section 8 of the Investment Company Act of 1940. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock of the Issuer directly held by each of 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”), which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon the exercise of the Prefunded Warrants (as defined below), subject to the limitations on exercise described below. The information set forth below is based upon 59,059,343 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as ame

View Full Filing

View this SC 13G/A filing on SEC EDGAR